NanoViricides, Inc. (NASDAQ:NNVC) | Finanzwire

Basculer en Français

8302	Companies
115129	Keywords
55450	Articles
62533	Press releases

Home
Companies
NanoViricides, Inc.

BRIEF

published on 05/20/2024 at 12:35, 6 months 1 day ago

NV-387 Shows Promising Results in Treating Lethal RSV Infection in Animal Study

NanoViricides NV-387 Clinical Trials Antiviral RSV
PRESS RELEASE

published on 05/20/2024 at 12:30, 6 months 1 day ago

Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure
NanoViricides, Inc. announces strong antiviral activity of NV-387 against RSV, Influenza A, and Coronaviruses in lethal lung infection models, potentially offering a cure for RSV infection

NV-387 Clinical Trials NanoViricides Inc. Antiviral RSV
BRIEF

published on 05/15/2024 at 12:35, 6 months 6 days ago

NanoViricides Reports Financial Update and Advancements in Clinical Trials

NanoViricides NV-387 Financial Report Clinical Trials Antiviral Treatment
PRESS RELEASE

published on 05/15/2024 at 12:30, 6 months 6 days ago

NanoViricides Has Filed its Quarterly Report
NanoViricides, Inc. reports advancing NV-387 to Phase II Clinical Trial for RSV infection treatment. Financial status and future plans discussed

NV-387 Phase II Clinical Trial NanoViricides Inc. RSV Infection Antiviral Nanomedicines
BRIEF

published on 05/14/2024 at 12:35, 6 months 7 days ago

NanoViricides Announces Breakthrough in RSV Treatment with NV-387

NanoViricides NV-387 Pharmaceutical Innovation RSV Treatment Antiviral Research
PRESS RELEASE

published on 05/14/2024 at 12:30, 6 months 7 days ago

A Novel Broad-Spectrum Antiviral with Activity Against RSV
NanoViricides, Inc. announces complete survival of animals lethally infected with RSV in lungs upon NV-387 oral treatment. Promising antiviral activity shown in study

NV-387 NanoViricides Inc. Antiviral Treatment RSV Infection Lung Infection
BRIEF

published on 05/08/2024 at 12:35, 6 months 13 days ago

NanoViricides Announces Promising Results with NV-387 in Potentially Treating Smallpox and Mpox

NanoViricides NV-387 Tecovirimat Smallpox Mpox
PRESS RELEASE

published on 05/08/2024 at 12:30, 6 months 13 days ago

A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox
NanoViricides reports NV-387 shows strong orthopoxvirus activity against Smallpox/Mpox via inhalation and skin transmission. Study highlights efficacy in lethal animal models, supporting clinical development potential

NanoViricides NV-387 Clinical Development Orthopoxvirus Antiviral
BRIEF

published on 05/06/2024 at 12:35, 6 months 15 days ago

NanoViricides Reports Promising Results for NV-387 in Treating Influenza A

NanoViricides NV-387 Antiviral Drugs Influenza A H5N1 Bird Flu
PRESS RELEASE

published on 05/06/2024 at 12:30, 6 months 15 days ago

A Novel Broad-Spectrum Antiviral with Activity Against Influenza A
NanoViricides reports strong anti-influenza activity of NV-387, suggesting effectiveness against H5N1 bird flu virus. Results show superior performance to approved drugs. Further studies needed for confirmation

NanoViricides NV-387 Anti-influenza H5N1 Drug

Accesswire

Published on 11/22/2024 at 00:00, 4 hours 26 minutes ago

Gratomic Announces Company and Operational Update
Published on 11/21/2024 at 22:05, 6 hours 21 minutes ago

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 6 hours 36 minutes ago

Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 8 hours 11 minutes ago

Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 8 hours 16 minutes ago

For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 19:01, 9 hours 25 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/21/2024 at 18:36, 9 hours 50 minutes ago

Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 10 hours 28 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 10 hours 35 minutes ago

LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 10 hours 35 minutes ago

2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.

Les Echos

Published on 11/21/2024 at 06:58, 21 hours 28 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 9 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 10 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 10 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 20 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE